Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy

Brain Research

Volumn 1008, Issue 2, 2004, Pages 236-244

  Jakus, Rita ^a   Graf, Marton ^a   Ando, Romeo D ^a   Balogh, Brigitta ^a   Gacsalyi, Istvan ^b   Levay, Gyorgy ^b   Kantor, Sandor ^a   Bagdy, Gyorgy ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

5 HT1A receptor; Absence epilepsy; AMPA receptor; Excitatory amino acids: pharmacology; Glutamate; GYKI 52466; GYKI 53405; Neurotransmitters, modulators, transporters, and receptors; Serotonin; Sleep; Spike wave discharge; Talampanel

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 7 ACETYL 5 (4 AMINOPHENYL) 8 METHYL 8,9 DIHYDRO 7H 1,3 DIOXOLO[4,5 B][2,3]BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; GYKI 53405; SEROTONIN 1A AGONIST; TALAMPANEL; UNCLASSIFIED DRUG;

ABSENCE; ALERTNESS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CONTROLLED STUDY; DOSE RESPONSE; EPILEPTIC DISCHARGE; IMMOBILIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; REGULATORY MECHANISM; SLOW WAVE SLEEP; SPIKE WAVE; WAKEFULNESS;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; AROUSAL; BEHAVIOR, ANIMAL; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EPILEPSY, ABSENCE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; RATS; RECEPTORS, AMPA; SEROTONIN AGONISTS; SLEEP; WAKEFULNESS;

EID: 2442492165     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.01.087     Document Type: Article

References (43)

1. Abraham G., Solyom S., Csuzdi E., Berzsenyi P., Ling I., Tarnawa I., Hamori T., Pallagi I., Horvath K., Andrasi F., Kapus G., Harsing L.G. Jr., Kiraly I., Patthy M., Horvath G. New non competitive AMPA antagonists. Bioorg. Med. Chem. 8(8):2000;2127-2143
2. Avanzini G., Vergnes M., Spreafico R., Marescaux C. Calcium-dependent regulation of genetically determined spike and waves by the reticular thalamic nucleus of rats. Epilepsia. 34:1993;1-7
3. Bradford H.F. Glutamate, GABA and epilepsy. Prog. Neurobiol. 47:1995;477-511
4. Chapman A.G. Excitatory neurotransmission and antiepileptic drug development: a status report. Pedley T.A., Meldrum B.S. Excitatory Neurotransmission and Antiepileptic Drug Development: A Status Report. vol. 6:1995;1-21 Churchill Livingstone, Edinburgh, Scotland
5. Chapman A.G. Glutamate receptors in epilepsy. Prog. Brain. Res. 116:1998;371-383
6. Chapman A.G. Glutamate and epilepsy. J. Nutr. 130:2000;1043S-1045S
7. Chapman A.G., Smith S.E., Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 9:1991;92-96
8. Chapman A.G., Elwes R.D., Millan M.H., Polkey C.E., Meldrum B.S. Role of glutamate and aspartate in epileptogenesis: contribution of microdialysis studies in animal and man. Epilepsy Res., Suppl. 12:1996;239-246
9. Chapman A.G., Woodburn V.L., Woodruff G.N., Meldrum B.S. Anticonvulsant effect of reduced NMDA receptor expression in audiogenic DBA/2 mice. Epilepsy Res. 26:1996;25-35
10. Coenen A.M., Drinkenburg W.H., Inoue M., van Luijtelaar E.L. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Res. 12(2):1992;75-86
11. Collingridge G.L., Lester R.A. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 41:1989;143-210
12. De Sarro G., Chimirri A., De Sarro A., Gitto R., Grasso S., Giusti P., Chapman A.G. GYKI 52466 and related 2, 3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J. Pharmacol. 294:1995;411-422
13. De Sarro A., De Sarro G., Gitto R., Grasso S., Micale N., Zappala M. Synthesis and anticonvulsant activity of new 2, 3-benzodiazepines as AMPA receptor antagonists. Farmaco. 54:1999;178-187
14. Doczi J., Banczerowski-Pelyhe I., Barna B., Vilagi I. Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices. Brain Res. Bull. 49:1999;435-440
15. Donevan S.D., Yamaguchi S.I., Rogawski M.A. Non-N-methyl-D-aspartate receptor receptor antagonism by 3-N-subtituted 2, 3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther. 271:1994;25-29
16. Durmuller N., Craggs M., Meldrum B.S. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174
17. Filakovszky J., Gerber K., Bagdy G. A serotonin-1A receptor agonist and N-methyl-D-aspartate receptor antagonist oppose each other's effects in a genetic rat epilepsy model. Neurosci. Lett. 261:1999;89-92
18. Filakovszky J., Kantor S., Halasz P., Bagdy G. 8-OH-DPAT and MK-801 affect epileptic activity independently of vigilance. Neurochem. Int. 38:2001;551-556
19. Gerber K., Filakovszky J., Halasz P., Bagdy G. The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 807:1998;243-245
20. Herrling P.L., Emre M., Watkins J.C. D-CPPene (SDZ EAA-494) - a competitive NMDA antagonist: pharmacology and results in humans. Herrling P.L. D-CPPene (SDZ EAA-494) - A Competitive NMDA Antagonist: Pharmacology and Results in Humans. 1997;7-21 Academic Press, San Diego, CA
21. Kamiński R.M., Van Rijn C.M., Turski W.A., Czuczwar S.J., Van Luijtelaar G. AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. Eur. J. Pharmacol. 430(2-3):2001 (Nov. 2);251-259
22. Lodge D. Subtypes of glutamate receptors: historical perspectives on their pharmacological differentiation. Monaghan D.T., Wenthold R.J. Subtypes of Glutamate Receptors: Historical Perspectives on Their Pharmacological Differentiation. 1997;1-38 Humana Press, Totowa, NJ
23. Löscher W., Hönack D. Effects of the non-NMDA receptor antagonists NBQX and 2, 3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113:1994;1349-1357
24. Löscher W., Annies R., Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194
25. McCormick D.A. Neurotransmitter actions in the thalamus and cerebral cortex. J. Clin. Neurophysiol. 9:1992;212-223
26. Meldrum B.S. The role of glutamate in epilepsy. Neurology. 44:1994;S14-S23
27. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 130:2000;1007S-1015S
28. Meldrum B.S., Chapman A.G. Excitatory amino acid receptors and antiepileptic drug development. Adv. Neurol. 79:1999;965-978
29. Meldrum B.S., Akbar M.T., Chapman A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. 36:1999;189-204
30. Paxinos G., Watson C. The Rat Brain. 1986;Academic Press, San Diego, CA
31. Peeters B.W., Van Rijn C.M., Van Luijtelaar E.L., Coenen A.M. Antiepileptic and behavioural actions of MK-801 in an animal model of spontaneous absence epilepsy. Epilepsy Res. 3:1989;178-181
32. Peeters B.W., Ramakers G.M., Vossen J.M., Coenen A.M. The WAG/Rij rat model for nonconvulsive absence epilepsy: involvement of nonNMDA receptors. Brain Res. Bull. 33:1994;709-713
33. Rogawski M.A. Epilepsy. Pullan L., Patel J. Epilepsy. 1996;1-38 Human Press, Totowa, NJ
34. Rogawski M.A., Donevan S.D. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol. 79:1999;947-963
35. Snead O.C. 3rd Basic mechanisms of generalized absence seizures. Ann. Neurol. 37:1995;146-157
36. Steriade M. Synchronized activities of coupled oscillators in the cerebral cortex and thalamus at different levels of vigilance. Cereb. Cortex. 7:1997;583-604
37. Swedberg M.D.B., Jacobsen P., Honoré T. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2, 3-dihydroxy-6-nitro-7- sulfamoylbenzol(f)quinoxaline (NBQX). J. Pharmacol. Exp. Ther. 274:1995;1113-1121
38. Szabados T., Gigler G., Gacsalyi I., Gyertyan I., Levay G. Comparison of anticonvulsive and acute neuroprotective activity of three 2, 3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res. Bull. 55:2001;387-391
39. Szekely J.I., Kedves R., Mate I., Torok K., Tarnawa I. Apparent antinociceptive and anti-inflammatory effects of GYKI 52466. Eur. J. Pharmacol. 336(2-3):1997;143-154
40. Tarnawa I., Vizi E.S. 2, 3-Benzodiazepine AMPA antagonists. Restor. Neurol. Neurosci. 13:1998;41-57
41. Van Luijtelaar E.L.J.M., Coenen A.M.L. The Wag/Rij model for generalized absence seizures. Manelis E.B.E.A. The Wag/Rij Model for Generalized Absence Seizures. vol. 17:1989;78-83 Raven Press, New York
42. Vilagi I., Takacs J., Gulyas-Kovacs A., Banczerowski-Pelyhe I., Tarnawa I. Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. 59:2002;35-40
43. Yamaguchi S., Donevan S.D., Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:1993;179-184